Sanofi SA
Novavax stock jumps 50% as Sanofi offer kicks off turning issue for battling vaccine maker
A vial labelled “Novavax V COVID-19 Vaccine” is witnessed in this illustration taken January 16, 2022. Dado Ruvic | Reuters Shares of Novavax jumped as a lot as 50% on Monday as Wall Road cheered the firm’s new multibillion-dollar offer with French drugmaker Sanofi that sparked a spectacular turnaround for the having difficulties vaccine maker. […]
Read More
Shares producing the largest moves premarket: Yelp, Sweetgreen, Novavax, Akamai Systems and more
Look at out the corporations producing headlines right before the bell. Akamai Systems — Shares of the cloud enterprise fell a lot more than 10% soon after issuing weak steering for the 2nd quarter. Akamai sees adjusted earnings ranging from $1.51 to $1.56 for each share on income of $967 million to $986 million. Analysts […]
Read More
Novavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop combination shots
A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Patrick Van Katwijk | Getty Images Novavax on Friday said it has signed a multibillion-dollar deal with French drugmaker Sanofi to co-commercialize the company’s Covid […]
Read More
Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial
The coronal view of a human brain of a patient suffering from Parkinson’s disease Sherbrooke Connectivity Imaging Lab | Getty Images A highly popular class of drugs for diabetes and obesity is showing early potential to help patients with Parkinson’s disease, too. An older diabetes treatment called lixisenatide helped slow the progression of motor disability […]
Read More
The 11 GRANOLAS shares power Europe to file highs, drawing Magnificent Seven comparisons
The German share selling price index DAX graph is pictured at the inventory trade in Frankfurt, Germany, January 19, 2024. Employees | Reuters Above the last 12 months, just 11 shares manufactured up half of the gains that driven the pan-European Stoxx 600 stock index to a document-large close on Friday. Earlier this month, Goldman […]
Read More
The 11 GRANOLAS stocks power Europe to record highs, drawing Magnificent Seven comparisons
The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024. Staff | Reuters Over the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday. Earlier this month, Goldman Sachs […]
Read More
Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
US Senator Bernie Sanders, Independent of Vermont, speaks during a rally by the People’s Action, protesting pharmaceutical companies’ lobbying against allowing Medicare to negotiate lower prescription drug prices, outside Pharmaceutical Research and Manufacturers of America (PhRMA) headquarters in Washington, DC, September 21, 2021. Saul Loeb | AFP | Getty Images The CEOs of Merck and […]
Read More
The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming space
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Michael Siluk | UCG | Getty Images Drugmakers have been scrambling to join a two-horse race to lead the market for popular weight loss drugs, which could […]
Read More
Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
Medical personnel use a mammogram to examine a woman’s breast for breast cancer. Hannibal Hanschke | dpa | Picture Alliance | Getty Images SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead. […]
Read More
If you can't build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by 2030 , other pharmaceuticals companies — […]
Read More